Introduction
============

The chloramphenicol--florfenicol resistance (*cfr*) gene encodes a methyltransferase that modifies position A-2503 in bacterial 23S rRNA and confers resistance to five classes of antibiotics (phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A) ([@B23]; [@B26]). These antibiotics have been widely used for the treatment of infections in human and animal ([@B12]; [@B18]). Since the first identification of the *cfr* gene in *Staphylococcus sciuri* isolates in 2000, it has been subsequently found in *Enterococcus* spp., *Bacillus* spp., *Streptococcus suis*, *Proteus vulgaris*, and *Escherichia coli* ([@B23]; [@B45], [@B42],[@B43]). In China, most *cfr*-positive isolates were derived from domestic animals (mainly pigs). In addition, plasmids and insertion sequences were implicated in *cfr* gene dissemination between species and genera ([@B33]).

Methicillin-resistant *Staphylococcus aureus* (MRSA) can cause a wide range of infections, including skin and soft-tissue infections as well as endocarditis and respiratory tract infections ([@B24]; [@B30]). Hospital-acquired MRSA (HA-MRSA) and community-acquired MRSA (CA-MRSA) are the primary origins for infections in humans ([@B46]). However, livestock-acquired MRSA (LA-MRSA) have been identified in pigs, ducks, poultry, and rats ([@B38]; [@B47]; [@B8]; [@B37]). Importantly, LA-MRSA containing the plasmid-borne *cfr* gene has been identified in infections of farmers suggesting zoonotic transmission ([@B47]; [@B6]).

In this study, we investigated the epidemiological characteristics and dissemination of the *cfr* gene in clinical MRSA isolates from animal and human sources. We compared the phenotypic and genotypic profiles of *cfr*-positive MRSA strains with *cfr*-negative MRSA strains.

Materials and Methods {#s1}
=====================

In total, 128 MRSA strains were isolated from pigs, chickens, and ducks in 10 different regions of China and from clinical patients in two different hospitals in Guangzhou, China during 2011--2016. All MRSA isolates were confirmed by MALDI-TOF/MS system (Shimadzu-Biotech, Japan), multiplex PCR amplification, and DNA sequencing of the *mecA* gene.

Minimum inhibitory concentrations (MIC) were determined using a standard agar dilution method -CLSI M100-S28 and VET01-A4/VET01-S2. The tested antibiotics were phenicols (florfenicol), lincosamides (clindamycin), oxazolidinones (linezolid), pleuromutilins (valnemulin), β-lactams (ampicillin and cefotaxime), macrolides (tylosin, azithromycin, and erythromycin) and ciprofloxacin, gentamycin, tetracycline, rifampicin, trimethoprim-sulfamethoxazole, vancomycin, and daptomycin. The MIC breakpoints of each antibiotic against MRSA were used as recommended by the current CLSI guidance (Clinical and Laboratory Standards Institute \[CLSI\], 2013, 2018). *S. aureus* ATCC 29213 was used as a quality control strain.

Detection of Resistance Genes
-----------------------------

The presence of the *cfr* gene in the MRSA strains was determined with PCR as described previously ([@B15]). Other genes that encoded resistance to phenicols (*fexA*), lincomycin \[*lnu*(A), (F)\], oxazolidinones (*optrA*), pleuromutilins (*vgaAV)*, macrolide--lincosamide--streptogramin B (*ermA-C*), macrolides (*ereA-B*), tetracycline \[*tet*(A), (C), (L), (M), and (K)\]. and aminoglycosides \[*aac(3*′*)-Ia, aac(3*′*)-IIc*, *aadA1*, *aadB*, *aph(3*′*)-II*, *aph(3*′*)-IV*, *aph(4*′*)-Ia*, and *aac(6*′*)-Ib*\] were identified by PCR using gene-specific primers (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}).

Molecular Typing
----------------

Genetic diversity of *cfr*-positive and -negative MRSA isolates was determined by *SmaI* pulsed-field gel electrophoresis (PFGE) ([@B35]). Comparison of PFGE patterns was performed with BioNumerics software (Applied Maths, Sint-Martens-Latem, Belgium). Dendrograms were generated using Dice similarity coefficient and analogical values to categorize identical PFGE types cut-offs were fixed at 100%. Further determinations of clonality were performed by multilocus sequence typing (MLST) and *spa* typing as described previously.^[1](#fn01){ref-type="fn"},[2](#fn02){ref-type="fn"}^ *Salmonella enterica* serotype Braenderup H9812 DNA was used as a molecular size marker ([@B35]).

Transformation of *cfr* Gene and Determination of *cfr* Location
----------------------------------------------------------------

Plasmid DNA from *cfr*-positive MRSA strains was extracted using a Qiagen Prep Plasmid Midi Kit (Qiagen, Hilden, Germany) and transferred into a recipient *S. aureus* strain RN4220 by electroporation using Gene Pulser apparatus (Bio-Rad, Hercules, CA, United States). Electrotransformants were selected on brain heart infusion (BHI) agar containing 8 μg/mL of florfenicol. The presence of *cfr* was further confirmed by PCR ([@B14]). To determine the location of *cfr* gene, DNA was separated by PFGE after treatment with *S1* nuclease (Takara, Dalian, China) and plasmids carrying *cfr* were identified by Southern blot hybridization using a digoxigenin-labeled *cfr* probe (Roche, Mannheim, Germany) according to the manufacturer's instruction.

Genetic Environment of *cfr* Gene
---------------------------------

The genetic environment surrounding *cfr* was determined by PCR mapping, inverse PCR, and sequencing ([@B39]). The primers used to determine the regions upstream and downstream of *cfr* gene and reference sequences containing the *cfr* gene used for PCR mapping are listed in Supplementary Table [S2](#SM1){ref-type="supplementary-material"}. The obtained DNA sequences were analyzed using BLAST,^[3](#fn03){ref-type="fn"}^ and then compared to those deposited in GenBank.

Statistical Analyses
--------------------

Statistical significance for the comparison of prevalence data and proportions was determined using a χ^2^ test. *P* \< 0.05 was consideredto be statistical significant.

Results
=======

Antimicrobial Susceptibility and Presence of Resistance Genes
-------------------------------------------------------------

We demonstrated that \>80% of the 128 MRSA isolates were resistant to all tested antimicrobial agents with the exception of sulfamethozaxole/trimethoprim (43.8%), rifampicin (21.1%), linezolid (1.56%), vancomycin (0%), and daptomycin (0%) (Figure [1](#F1){ref-type="fig"}). Importantly, resistance rates in *cfr*-positive strains were higher than in *cfr*-negative strains for sulfamethozaxole/trimethoprim (60 vs. 40.7%) and rifampicin (30 vs. 19.4%) (Figure [1](#F1){ref-type="fig"}). In addition, the proportion of isolates with increased linezolid MIC (≥2 μg/mL) was significantly higher in the *cfr*-positive MRSA vs. the *cfr*-negative MRSA (40 vs. 6.5%, *P* \< 0.001) (Supplementary Table [S3](#SM1){ref-type="supplementary-material"}).

![Antibiotic resistance in MRSA strains from animals and humans. GEN, gentamicin; TYL, tylosin; AZM, azithromycin; ERY, erythromycin; CTX, cefotaxime; AMP, ampicillin; CLDM, clindamycin; TET, tetracycline; FFC, florfenicol; CIP, ciprofloxacin; VAL, valnemulin; S/T, sulfamethoxazole/trimethoprim; RIF, rifampicin; LIN, linezolid; VAN, vancomycin; DAP, daptomycin.](fmicb-09-02925-g001){#F1}

In addition, 20 of the 128 MRSA strains (15.6%) harbored the *cfr* gene, and included 13 isolates from pigs (10.2%), three from chickens (2.3%), one from duck (0.8%), and three from humans (2.3%). Interestingly, all of the *cfr*-positive MRSA strains also carried the *fexA*, *ermC*, *ereA*, and *aadA1* genes (Table [1](#T1){ref-type="table"}). In addition, the prevalence of all the other tested antibiotic resistance genes (ARGs) was higher in the *cfr*-positive MRSA isolates than in *cfr*-negative MRSA isolates, especially for the *optrA*, *ereB*, *aac (3*′*)-IIc*, and *aph (3*′*)-IV* genes (*P* \< 0.05; Figure [2](#F2){ref-type="fig"}).

###### 

Background information and characteristics of *cfr*-positive MRSA.

  Strains^a^      ST-*spa*      Year   Source    Resistance profile^b^                                                                                          Other resistance genes^c^                              *cfr* location (size, kb)   *cfr* genetic environmental types
  --------------- ------------- ------ --------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ --------------------------- -----------------------------------
  [5ZX13]{.ul}    ST9-t7880     2012   Pig       [FFC]{.ul}, [AMZ]{.ul}, [ERY]{.ul}, [CLDM,]{.ul} [CIP]{.ul}, AMP, CTX, TET, GEN, TYL, RIF, VAL                 *[fexA]{.ul}, [ermC]{.ul}* *optrA*, *ermA*             Plasmid (∼50)               I
  [5ZB12]{.ul}    ST9-t899      2011   Pig       [FFC,]{.ul} [AMZ]{.ul}, [ERY]{.ul}, [CLDM,]{.ul} [CIP]{.ul}, [TYL]{.ul}, AMP, CTX, TET, GEN, S/T, VAL          *[fexA]{.ul}, [ermC,]{.ul}* *optrA*                    Plasmid (∼50)               I
  [6ZB3]{.ul}     ST9-t899      2012   Pig       [FFC,]{.ul} [AMZ]{.ul}, [ERY]{.ul}, [CLDM]{.ul}, [CIP]{.ul}, AMP, CTX, TET, GEN, TYL, S/T, VAL                 *[fexA]{.ul}*, *[ermC]{.ul}*, *optrA*                  Plasmid (∼50)               I
  [2ZG3]{.ul}     ST9-t899      2012   Pig       [FFC]{.ul}, [AMZ]{.ul}, [ERY]{.ul}, [CLDM]{.ul}, [CIP]{.ul}, [TYL]{.ul}, AMP, CTX, TET, GEN, TIG, S/T, VAL     *[fex]{.ul}A, [erm]{.ul}C*, *ermA*                     Plasmid (∼50)               I
  [2ZX3]{.ul}     ST9-t899      2012   Pig       [FFC]{.ul}, [AMZ]{.ul}, [ERY]{.ul}, [CLDM]{.ul}, [CIP]{.ul}, AMP, CTX, TET, GEN, TYL, RIF, VAL                 *[fexA]{.ul}*, *[ermC]{.ul}*[,]{.ul} *optrA*, *ermA*   Plasmid (∼50)               I
  [5ZB14]{.ul}    ST9-t899      2012   Pig       [FFC]{.ul}, [AMZ]{.ul}, [ERY]{.ul}, [CLDM]{.ul}, [TYL]{.ul}, AMP, CTX, TET, GEN, CIP, S/T, VAL                 *[fexA]{.ul}*, *[ermC]{.ul}*, *optrA*                  Plasmid (∼50)               I
  [N3]{.ul}       ST9-t899      2012   Pig       [FFC]{.ul}, [AMZ]{.ul}, [ERY]{.ul}, [CLDM]{.ul}, [CIP]{.ul}, AMP, CTX, TET, TIG, GEN, TYL, VAL                 *[fexA]{.ul}*, *[ermC]{.ul}*, *opt*r*A*, *ermA*        Plasmid (∼50)               I
  [25FS35]{.ul}   ST9-t899      2016   Pig       [FFC]{.ul}, [AMZ]{.ul}, [ERY]{.ul}, [CLDM]{.ul}, [CIP]{.ul}, AMP, CTX, TET, RIF, TYL, S/T, VAL                 *[fexA]{.ul}*, *[ermC]{.ul}*, *optrA*                  Plasmid (∼50)               I
  [HYB6]{.ul}     ST9-t899      2016   Pig       [FFC]{.ul}, [AMZ]{.ul}, [ERY]{.ul}, [CLDM]{.ul}, [TYL]{.ul}, AMP, TIG,CTX, TET, GEN, CIP, VAL                  *[fexA]{.ul}*, *[ermC]{.ul}*, *optrA*, *ermA*          Plasmid (∼50)               I
  [YFC28]{.ul}    ST9-t899      2014   Chicken   [FFC]{.ul}, [AMZ]{.ul}, [ERY]{.ul}, [CLDM,]{.ul} [TYL,]{.ul} [TET]{.ul}, [GEN]{.ul}, AMP, CTX, RIF, CIP, VAL   *fexA*, *[ermC]{.ul}*, *optrA*, *ermA*                 Plasmid (∼50)               I
  [HB119]{.ul}    ST9-t899      2016   Chicken   [FFC]{.ul}, [AMZ]{.ul}, [ERY]{.ul}, [CLDM]{.ul}, AMP, CTX, TET, GEN, CIP, TYL, VAL                             *[fexA]{.ul}*, *[ermC]{.ul}*, *ermA*                   Plasmid (∼50)               I
  [25FS24]{.ul}   ST9-t899      2016   Pig       [FFC]{.ul}, [AMZ]{.ul}, [ERY]{.ul}, [CLDM]{.ul}, [TYL]{.ul}, CTX, TET, RIF, CIP, S/T, VAL                      *[fexA]{.ul}*, *[ermC]{.ul}*, *optrA*                  Plasmid (∼7.1)              II
  [26FS31]{.ul}   ST9-t899      2016   Chicken   [FFC]{.ul}, [AMZ]{.ul}, [ERY]{.ul}, [CLDM]{.ul}, [TYL,]{.ul} CTX, TET, GEN, CIP, BAC, VAL                      *[fexA]{.ul}*, *[ermC]{.ul}*, *optrA*                  Plasmid (∼7.1)              II
  6Y2C            ST398-t7829   2012   Duck      AMP, CTX, TET, FFC, GEN, CIP,TYL, AMZ, ERY, RIF, CLDM, S/T, VAL                                                *fexA*, *ermC, optrA*, *ermA*                          ND                          
  6ZB5            ST9-t899      2012   Pig       AMP, CTX, TET, FFC, GEN, CIP, TYL, TIG, AMZ, ERY, CLDM, VAL                                                    *fexA*, *ermC*, *optrA*, *ermA*                        ND                          
  7SX2            ST9-t899      2012   Pig       AMP, CTX, TET, FFC, GEN, CIP, TYL, AMZ, ERY, CLDM, VAL                                                         *fexA,* *ermC*, *optrA*, *ermA*                        ND                          
  N4-2            ST9-t899      2012   Pig       AMP, CTX, TET, FFC, GEN, CIP, TYL, RIF, AMZ, ERY, CLDM, S/T, VAL                                               *fexA*, *ermC*, *optrA*, *ermA*                        ND                          
  BA13            ST9-t899      2016   Human     AMP, CTX, TET, FFC, GEN, CIP, TYL, RIF, AMZ, ERY, CLDM, S/T, VAL                                               *fexA*, *ermC*, *optrA*                                ND                          
  161429          ST764-t1084   2016   Human     AMP, CTX, TET, FFC, GEN, CIP, TYL, AMZ, ERY, CLDM, S/T, VAL                                                    *fexA*, *ermC*, *optrA*, *ermA*                        ND                          
  161494          ST764-t1084   2016   Human     AMP, CTX, TET, FFC, GEN, CIP, TYL, AMZ, ERY, CLDM, VAL                                                         *fexA*, *ermC*, *optrA*, *ermA*                        ND                          

a

Isolates from electrotransformants are underlined.

b

Resistance profiles of transferred strains are underlined. AMP, ampicillin; CTX, cefotaxime; TET, tetracycline; FFC, florfenicol; GEN, gentamicin; CIP, ciprofloxacin; TYL, tylosin; AZM, azithromycin; ERY, erythromycin; CLDM, clindamycin; S/T, sulfamethoxazole/trimethoprim; RIF, rifampicin; VAL, valnemulin.

c

Genes that were co-transferred with cfr are underlined. ND, not determined.

![Positive detection rates of genes related to antibiotic resistance in the study MRSA strains. Detection rates between the *cfr*-positive and *cfr*-negative MRSA strains were determined using the χ^2^ test. ^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01 *cfr*-positive MRSA strains vs. *cfr*-negative MRSA strains.](fmicb-09-02925-g002){#F2}

Molecular Typing
----------------

The 128 MRSA strains contained eight ST types and seven *spa* types, and ST9 (82.0%, 105/128) and *spa* type t899 (80.5%, 103/128) were predominated. In the *cfr*-positive MRSA isolates, three ST types and four *spa* types were observed, and ST9 (85%, 17/20) and *spa* type t899 (75%, 15/20) were also the most prevalent of these types. We observed 12 different profiles using a combination of MLST and *spa* typing in the 128 MRSA isolates. ST9-t899 (78.9%, 101/128) and ST764-t1084 (6.3%, 8/128) were the most and second most ST-*spa* types, respectively (Supplementary Table [S4](#SM1){ref-type="supplementary-material"}).

We also found 20 different PFGE profiles in the *cfr*-positive and 10 *cfr*-negative MRSA isolates (Figure [3](#F3){ref-type="fig"}). PFGE analysis suggested that MRSA isolates in the current study were epidemiologically unrelated clones.

![PFGE fingerprint patterns of *SmaI*-digested total DNA preparations from 20 MRSA strains harboring *cfr* and 10 *cfr*-negatives MRSA strains. A similarity cutoff of 100% was used to identify a PFGE cluster. Guangzhou (GZ), Qinhuangdao (QHD), Foshan (FS), Shandong (SD), Huadu (HD), and Heyuan (HY). "+", *cfr*-positive; "--" \<LIST\>*cfr*-negative.](fmicb-09-02925-g003){#F3}

Transfer of *cfr* and Plasmids Analyses
---------------------------------------

The *cfr* gene from 13 of the 20 *cfr*-positive MRSA isolates were successfully transferred to a recipient strain (*S. aureus* RN4220) and showed 4- to 64-fold increases in the MICs of florfenicol as compared with the recipient strain lacking the *cfr* gene. In addition, *cfr* gene transfenerated strains were resistant to erythromycin, azithromycin, and clindamycin. Co-transfer of *cfr* with *fexA* and *ermC* genes were found in eight of 13 electrotransformants. *S1*-PFGE and Southern blot hybridizations revealed that the *cfr* genes were located on plasmids with sizes of 50 kb (*n* = 11) or 7.1 kb (*n* = 2) (Table [1](#T1){ref-type="table"}).

Genetic Environment of *cfr* Gene
---------------------------------

The genomic structure surrounding *cfr* in the 13 *cfr*-carrying electrotransformants showed two different genetic contexts. Type I was the most common structure observed in 11 of 13 among which the *cfr* gene was located on ∼ 50 kb plasmids. The 9,880 bp *cfr*-containing regions comprised a truncated *tnpA* (*DeltatnpA*), *istA*, *istB*, *cfr*, *tnpB*, *tnpC*, *orf138*, and *fexA*. This was a Tn*558* variant with a 5′ deletion of *tnpB* by insertion of the IS*21-558* element (*istA-B*) and *cfr* in the same orientation. Type II was similar to that in plasmid pHNCR35 (KF861983), pSS-02 (JX827253), pHK01 (KC820816), and pSA737 (KC206006). Type II was found in two electrotransformants among which the complete nucleotide sequences of 7,057-bp circular plasmids harboring *cfr* (p26FS31 and p25FS24) were obtained. A plasmid comparison based on a BLAST query revealed that p26FS31 and p25FS24 were identical to plasmid pSS-03 (JQ219851) and pHNLKJC2 (KF751701). These plasmids consisted of five open reading frames (ORF) (*rep*-Delta*pre/mob-cfr-pre/mob*-*ermC*) (Figure [4](#F4){ref-type="fig"}).

![The genetic context surrounding the *cfr* gene in plasmids and their structural comparison with plasmids possessing have \>98% similarity. The arrows indicate the positions and directions of the transcription of each gene. Gray shaded regions indicate homology \>98%. "Delta" represents a truncated gene.](fmicb-09-02925-g004){#F4}

Discussion
==========

In this study, we investigated the prevalence of *cfr* in 128 MRSA strains isolated from animals and humans in China. Our study showed a significantly higher positive rate of *cfr* in LA-MRSA strains from animals (15.17%) than that recently reported in domestic studies (1.11--3.46%) ([@B17]; [@B18]). In addition, *cfr* was also present in one MRSA isolate from domestic duck. To the best of our knowledge, this is the first report on the *cfr* gene in MRSA strains from waterfowl. This finding may implicate a recent and rapid dissemination process of *cfr* in MRSA strains from different food animals in China. Moreover, the prevalence of *cfr* in MRSA strains from humans (2.34%) was higher in the current study than that previously reported for clinical patients (0.30%) ([@B3]), but lower in isolates from a teaching hospital in a different region of China (9.38%) ([@B36]).

Most of the *cfr*-positive MRSA strains in the current study presented a multidrug-resistant phenotype and harbored diverse ARGs. These observations were similar to the high occurrence of multidrug resistance previously reported in *cfr*-positive MRSA isolates from swine farms and retail meat in China ([@B50]; [@B18]). In addition, the *cfr* gene has been reported to be associated with oxazolidinone resistance in several studies ([@B32]; [@B33]), but it only mediated low levels of resistance to this antibiotic class. In the current study, we found that the proportion of MRSA isolates with increased linezolid MICs in the *cfr*-positive MRSA strains was higher than in the *cfr*-negative MRSA strains. Interestingly, we also determined that the majority of *cfr*-positive MRSA isolates harbored *optrA*, which is in agreement with previous reports suggesting that *optrA* and *cfr* coexist ([@B16]; [@B10]). In addition to *optrA*, our study *cfr*-positive MRSA isolates also co-carried *fexA* and *ermC*, which is also consistent with previous studies ([@B22]). This linked the cotransmission of *fexA* and *ermA-C* with *cfr* gene in diverse plasmids from coagulase-negative *Staphylococci* as well as *Enterobacteriaceae* of different origins ([@B42], [@B41]; [@B49]). Moreover, we observed different ratios of *ermA*, *ermB*, and *ermC* in our study strains that may be related to the location of the genes. For instance, *ermA* and *ermB* are primary chromosomal genes, while *ermC* gene is often plasmid-borne ([@B31]; [@B13]). The *ermB* was present in a minority of our strains, while *ermA* and *ermC* were frequent in MRSA strains ([@B20]; [@B21]). Furthermore, we found that the majority of the *cfr* genes were located on plasmids. Therefore, these factors may have influenced on the high ratio of *ermC* as we observed in the current studies.

Among all the study MRSA isolates, ST9 and t899 were the most prevalent ST and *spa* types, respectively. ST9 was reported as the predominant ST type in *S. aureus* isolates from animals in China ([@B6]), and sporadically occurred in Canada, England, Germany, and the United States ([@B27]; [@B11]; [@B9]). In other and our current study, ST9 in *S. aureus* isolates were also found in farmers ([@B11]; [@B9]; [@B34]). Emergence of the *cfr* gene in the prevalent ST9 MRSA isolates from pigs and pig-handlers would probably extend the potential reservoirs and expand the risk to human health ([@B49]; [@B48]). Since the ST398 was first identified in pigs and pig farmers in 2005 ([@B2]), it has become the most prevalent MLST-type in LA-MRSA in the United States and Europe ([@B2]; [@B7]; [@B1]). More importantly, the ST398 LA-MRSA carrying the *cfr* gene has been detected in Korea and other countries ([@B13]; [@B25]). Despite the wide and rapid dissemination of *cfr* gene in S. *aureus* isolates in China, to date, *cfr* was only identified in ST398 MRSA isolates from pigs ([@B19]).

In the current study, we also found a *cfr*-positive ST398 MRSA strain isolated from a duck indicating a possibility of widespread dissemination of the *cfr*-harboring ST398 LA-MRSA clone in China. In addition, all of the three *cfr*-positive MRSA isolates from patients were identified as ST764, the increased prevalent hybrid variant of the ST5 HA-MRSA lineage with the arginine catabolic mobile element (ACME) in China, Japan, and other Asian areas ([@B29]; [@B28]; [@B40]). These results indicated that *cfr*-positive MRSA isolates from animals and humans belonged to different ST types and were probably from epidemiologically unrelated MRSA clones.

In the MRSA isolates from food animals, the *cfr* genes were primarily located on two types of transferable plasmids with sizes of ∼ 50 and ∼ 7.1 kb. Two different genetic contexts surrounding *cfr* were found, and each was associated with one type of *cfr*-carrying plasmid. The predominant genetic context of *cfr* was found to be a Tn*558* variant in the large plasmids that co-carried *fexA*. This suggested that the acquisition of *cfr* could be involved in IS*21-558* mediated recombination. Importantly, the Tn*558* variant also occurred in *Bacillus*, *S. sciuri, Staphylococcus simulans*, and MRSA isolates from humans and swine ([@B39]; [@B18]).

In addition, we also found the *cfr* gene on small plasmids that co-carried *ermC* in MRSA isolates from food animals.These small plasmids were also identified in *Staphylococcus* and *Bacillus* species isolates from pigs ([@B44]). The high similarity of the genetic environment of *cfr* among diverse MRSA strains and sources indicated that horizontal transmission mediated by plasmids and transposons played a significant role in dissemination of *cfr*.

Conclusion
==========

Our studies demonstrated higher antibiotic resistance rates in the *cfr*-positive vs. -negative MRSA isolates. Horizontal transmission mediated by plasmids and transposons likely played an important role in co-dissemination of *cfr* with *fexA* and *ermC*. The transmission of similar *cfr*-carrying transposons and plasmids from diverse bacteria species and origins requires continued investigation.
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